Search

for
Search:

Learn

1 / 800 results

learn HMI-115

Experimental antibody that blocks the prolactin receptor

Is HMI-115 taken orally, applied on the scalp, or injected? In trials, HMI-115 is given by injection under the skin. It is an investigational drug, not approved or available anywhere.
Who can benefit the most from HMI-115: men, women, or people in transition? There is no published trial showing that any one group benefits most from HMI-115: the only released human efficacy data is a company press release on a 16-person Phase 1b, and it reported hair-count results for the 12 men only.
Is HMI-115 considered a safe option, or does it have strong side effects? HMI-115 is an experimental injected antibody, not a hormone blocker. Its published trials (a 29-woman Phase 1 safety study and a 12-week, 142-woman Phase 2 in endometriosis) reported acceptable tolerability but were too small and short to establish safety, and no peer-reviewed safety data exist for its use in hair loss.
All 5 questions on HMI-115 →

View more "hope hmi-115" in learn →

Community Join

5 / 1000+ results

community Hope Medicine's HMI-115 could be out in 2027 per Company Founder

34 upvotes 1 year ago

Hope Medicine's HMI-115 is expected to be released in 2027, with phase 3 trials currently recruiting. Concerns include the safety of targeting prolactin and the potential cost of the treatment.

community HMI-115 update: Chime Biologics and Hope Medicine Enter Manufacturing Agreement to Speed up the Launch of First-in-class Antibody Drug HMI-115 Targeting Endometriosis and Androgenic Alopecia

110 upvotes 2 years ago

Chime Biologics and Hope Medicine are speeding up the launch of a first-in-class antibody drug, HMI-115, for endometriosis and androgenic alopecia. The treatment involves a series of subcutaneous injections, has shown promising results in phase 1, and continues to promote hair regrowth even after the treatment is stopped.

community Is hmi 115 the cure? Or is it 🧢 just like cosmeRNA, brezula, pyrilutamide, and other 📞 ies

15 upvotes 2 years ago

HMI 115 is being discussed as a potential hair loss treatment, with skepticism due to past disappointments like cosmeRNA, brezula, and pyrilutamide. The user is questioning if they should be hopeful for new developments in the next six years.

community What's going on with hmi115? The Phase 2 was concluded Nov2024 but no news

13 upvotes 9 months ago

Hmi115, a prolactin receptor blocker, showed promise for hair growth, but results from Phase 2 trials have not been published. ABS-201, an AI-based analog, is expected to begin trials in December 2025, while commercialization of treatments like PP-405 is anticipated around 2027.

community HMI-115 Australian Phase 1 Trial completed?

20 upvotes 2 years ago

The post discusses the completion of the HMI-115 Australian Phase 1 Trial for hair loss treatment. The user speculates about the potential early release of the trial results.

View more "hope hmi-115" in community →

Research

2 / 1000+ results

research Recent approaches of antibody therapeutics in androgenetic alopecia

August 2024 in “Frontiers in Pharmacology”

This review discusses the potential of therapeutic antibodies as an alternative treatment for androgenetic alopecia, highlighting the initial development stages and the need for further validation and optimization of targets like the prolactin receptor and Interleukin-6 receptor.

research Recent Advances in Drug Development for Hair Loss

April 2025 in “International Journal of Molecular Sciences”

This review highlights the limitations of existing hair loss treatments like minoxidil and finasteride and suggests that future therapies may benefit from focusing on antibody and cell-based treatments, which offer targeted and potentially transformative options for managing hair loss disorders.

View more "hope hmi-115" in research →